Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.50
−$0.04 · -0.53%
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Latest quote
$7.50
−$0.04 · -0.53%
After-hours
$7.50
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Day range
Current $7.50
52-week range
Current $7.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
44
Mixed
Risk
58
Elevated Risk
Momentum
41
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Day range
Current $7.50
52-week range
Current $7.50
| Metric (USD) | FY2025 |
|---|---|
| Cost of goods sold | 24.18M USD |
| Gross profit | −24.18M USD |
| Research and development | 250.32M USD |
| Selling, general, and administrative | 88.63M USD |
| Operating expenses | 314.77M USD |
| Interest income | 15.57M USD |
| Interest expense | 837K USD |
| Depreciation and amortization | 24.18M USD |
| Operating income | −338.95M USD |
| Net income | −324.25M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.00
33.33% downsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.9M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM6.19M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF2.52M0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO1.54M0.01%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO1.31M0.01%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA1.15M0.01%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC755.49K0.06%1.33B USD0.60%$182.79-0.31%
ALPS Medical Breakthroughs ETFSBIO514.87K0.27%188.26M USD0.50%$53.945-0.34%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
